A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

While the drugs cannot cure or reverse the symptoms, they can slow the progression of the disease. Read more at ...

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...

A wonder drug that can slow down Alzheimer's disease is set to be approved for use in Britain. Lecanemab is the first treatment that has been found to curb the condition – slowing cognitive decline by ...

Lecanemab, on the other hand, is designed to slow the development of Alzheimer’s by removing amyloid beta. The medication is administered once every other week through an intravenous drip.

Nov 15, 2024 London – The European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval of sales of lecanemab to treat Alzheimer's disease.

The drug Lecanemab is now undergoing a regulatory approval process in Australia and other countries in the world, but its exorbitant cost means few will be able to access it. READ MORE ...